SCHEMBL20139798

SCHEMBL20139798

Fc1ccccc1Cn1nc(I)c2ccnnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 6/20 0.39
MAPT P10636 2/20 0.39
GRM2 Q14416 1/20 0.39
HPGD P15428 2/20 0.38
TSHR P16473 1/20 0.38
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PDE5A O76074 2/20 0.37
KDM4E B2RXH2 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CHRM1 P11229 1/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31120363 0.84 GRM2 (0.44) MEN1KMT2AALDH1A1MAPTGRM2
SCHEMBL174998 0.82 MAPT (0.53) MAPTL3MBTL1PDE5A
SCHEMBL20140328 0.81 BUB1 (0.37) MEN1KMT2AALDH1A1MAPTGRM2
SCHEMBL31120359 0.79 ADORA3 (0.37) MEN1KMT2AALDH1A1GRM2ADORA2A
SCHEMBL20141415 0.79 CFD (0.41) MEN1KMT2AALDH1A1MAPTADORA2A
SCHEMBL20140296 0.77 PDE5A (0.45) MEN1KMT2AALDH1A1ADORA2AADORA1
SCHEMBL31120357 0.76 ADORA3 (0.52) ADORA2AADORA1PDE5A
SCHEMBL7803805 0.76 ALDH1A1 (0.49) MEN1KMT2AALDH1A1MAPTGRM2
SCHEMBL15169360 0.75 PDE5A (0.52) MEN1KMT2AALDH1A1MAPTADORA2A
SCHEMBL174461 0.75 PDE5A (0.52) MEN1KMT2APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A MEN1 4141/4885KMT2A 4675/4885ALDH1A1 2298/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A MEN1 4168/4885KMT2A 4673/4885ALDH1A1 2355/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A MEN1 4168/4885KMT2A 4673/4885ALDH1A1 2355/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A MEN1 4141/4885KMT2A 4675/4885ALDH1A1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.